Crosstalk between NGS Receptors, TrkA & P75

NGS 受体之间的串扰,TrkA

基本信息

  • 批准号:
    7418936
  • 负责人:
  • 金额:
    $ 32.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-30 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Neurotrophins play key regulatory roles in cellular processes that are required for proper development and maintenance of the nervous system, such as cell survival/death, axon growth/guidance, and synaptic transmission/plasticity. Both Trk receptors and p75 participate in mediating these diverse neurotrophin actions, but p75 is mainly responsible for neurotrophin-dependent cell death at specific stages during development or under pathological conditions in the adult. The overall goal of this project is to understand the signaling mechanisms that underlie NGF's action regarding cell death and survival, with a focus on Rac and Rho, which are regulated by p75. P75 activates Rac in a prolonged manner that correlates with apoptosis, while co-activation of Trk/p75 leads to transient Rac activation and cell survival. These results suggest that the kinetics of Rac activation may be the key determinant in cellular outcome between cell survival and death. Regulation of Rho, on the other hand, may be determined by which coreceptor that p75 associates with: With neurotrophins/Trk, p75 inhibits Rho, while it activates Rho as a co-receptor for the Nogo receptor, NgR. P75 is often induced by injury in the adult nervous system and its expression in such cases has been linked to apoptosis. After the experimental injuries that induced p75 and cell death, Rho was activated, suggesting that controlling Rho activation by p75 will be critical in preventing cell death and degeneration after injuries. Our overall hypothesis is therefore that regulation of Rac and Rho by p75 determines the outcome between cell death and survival/regeneration. In an effort to understand the mechanisms by which p75 activates Rac and Rho, we discovered that the Kalirin family of guanidine exchange factors (GEF), Kalirin7 and 9, bind p75. Kalirin7 contains a Rac GEF domain, while Kalirin9 contains both Rac and Rho GEF domains. The specific aims include: (1) To determine the mechanisms of transient Rac activation by Kalirin7, (2) To determine whether prolonged Rac activation is necessary for apoptosis, and (3) To determine whether Kalirin9 is responsible for regulating the opposite's action of p75 for Rho activity both in vitro and in vivo after spinal cord injury. The outcome of this study will result in significant advancement of the current knowledge of NGF signaling, by elucidating the basic biochemical mechanisms behind the complex interplay between p75 and Trk, as well as p75 and NgR. A detailed understanding of the mechanisms may ultimately prompt therapeutic strategies for promoting regeneration and limiting degeneration in cases of neuronal injury and disease.
描述(由申请人提供):神经营养因子在神经系统正常发育和维持所需的细胞过程中发挥关键的调节作用,例如细胞存活/死亡,轴突生长/引导和突触传递/可塑性。Trk受体和p75都参与介导这些不同的神经营养因子作用,但p75主要负责在发育的特定阶段或成人病理条件下神经营养因子依赖性细胞的死亡。该项目的总体目标是了解NGF在细胞死亡和存活方面的作用的信号机制,重点关注由p75调节的Rac和Rho。P75激活Rac的时间较长,与细胞凋亡有关,而Trk/ P75的共激活导致Rac的短暂激活和细胞存活。这些结果表明,Rac活化动力学可能是细胞存活和死亡之间细胞结局的关键决定因素。另一方面,Rho的调节可能取决于p75与哪个辅助受体相关:与神经营养因子/Trk一起,p75抑制Rho,而它激活Rho作为Nogo受体NgR的辅助受体。P75通常由成人神经系统损伤引起,在这种情况下,P75的表达与细胞凋亡有关。在诱导p75和细胞死亡的实验损伤后,Rho被激活,这表明通过p75控制Rho的激活对于防止损伤后细胞死亡和变性至关重要。因此,我们的总体假设是p75对Rac和Rho的调控决定了细胞死亡和存活/再生之间的结果。为了了解p75激活Rac和Rho的机制,我们发现Kalirin家族的胍交换因子(GEF) Kalirin7和kalirin9与p75结合。Kalirin7包含Rac GEF域,而Kalirin9同时包含Rac和Rho GEF域。具体目的包括:(1)确定Kalirin7短暂激活Rac的机制;(2)确定细胞凋亡是否需要持续的Rac激活;(3)确定Kalirin9是否负责调节p75在脊髓损伤后体外和体内对Rho活性的相反作用。本研究的结果将通过阐明p75和Trk以及p75和NgR之间复杂相互作用背后的基本生化机制,从而显著提高当前对NGF信号传导的认识。对其机制的详细了解可能最终促使在神经元损伤和疾病的情况下促进再生和限制变性的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUNG OK YOON其他文献

SUNG OK YOON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUNG OK YOON', 18)}}的其他基金

Regulation of apoptosis and degeneration after spinal cord injury
脊髓损伤后细胞凋亡和变性的调控
  • 批准号:
    7575119
  • 财政年份:
    2007
  • 资助金额:
    $ 32.78万
  • 项目类别:
Regulation of apoptosis and degeneration after spinal cord injury
脊髓损伤后细胞凋亡和变性的调控
  • 批准号:
    7361344
  • 财政年份:
    2007
  • 资助金额:
    $ 32.78万
  • 项目类别:
Regulation of apoptosis and degeneration after spinal cord injury
脊髓损伤后细胞凋亡和变性的调控
  • 批准号:
    7257628
  • 财政年份:
    2007
  • 资助金额:
    $ 32.78万
  • 项目类别:
Crosstalk between NGS Receptors, TrkA & P75
NGS 受体之间的串扰,TrkA
  • 批准号:
    7561067
  • 财政年份:
    2000
  • 资助金额:
    $ 32.78万
  • 项目类别:
CROSSTALK BETWEEN NGF RECEPTORS, TRK A AND P75
NGF 受体、TRK A 和 P75 之间的串扰
  • 批准号:
    6559243
  • 财政年份:
    2000
  • 资助金额:
    $ 32.78万
  • 项目类别:
CROSSTALK BETWEEN NGF RECEPTORS, TRK A AND P75
NGF 受体、TRK A 和 P75 之间的串扰
  • 批准号:
    6394290
  • 财政年份:
    2000
  • 资助金额:
    $ 32.78万
  • 项目类别:
CROSSTALK BETWEEN NGF RECEPTORS, TRK A AND P75
NGF 受体、TRK A 和 P75 之间的串扰
  • 批准号:
    6285871
  • 财政年份:
    2000
  • 资助金额:
    $ 32.78万
  • 项目类别:
CROSSTALK BETWEEN NGF RECEPTORS, TRK A AND P75
NGF 受体、TRK A 和 P75 之间的串扰
  • 批准号:
    6617994
  • 财政年份:
    2000
  • 资助金额:
    $ 32.78万
  • 项目类别:
CROSSTALK BETWEEN NGF RECEPTORS, TRK A AND P75
NGF 受体、TRK A 和 P75 之间的串扰
  • 批准号:
    6529609
  • 财政年份:
    2000
  • 资助金额:
    $ 32.78万
  • 项目类别:
Crosstalk between NGS Receptors, TrkA & P75
NGS 受体之间的串扰,TrkA
  • 批准号:
    7015045
  • 财政年份:
    1999
  • 资助金额:
    $ 32.78万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.78万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了